Two randomized trials have shown that abiraterone plus prednisone and androgen-deprivation therapy (ADT) improved survival as compared with ADT alone in patients with de novo metastatic hormone-sensitive prostate cancer (mHSPC) (hazard ratio 0.62–0.63). The most important side-effects (hypokalemia and hypertension) were mild (mostly grade 1–2) and easy to manage. For patients with high-risk locally advanced disease or lymph node metastases abiraterone plus prednisone and ADT increased progression-free survival. However, the data is still immature to show overall survival benefit in this patient subgroup. For patients with mHSPC, combination therapy with abiraterone plus prednisone and ADT can be considered a new standard of care.

abirateron · androgeendeprivatietherapie · gemetastaseerd hormoonnaïef prostaatcarcinoom, abiraterone · androgen-deprivation therapy · metastatic hormone-sensitive prostate cancer
dx.doi.org/10.1007/s13629-017-0196-x, hdl.handle.net/1765/128295
Tijdschrift voor Urologie
Department of Orthopaedics

van Soest, R.J, van Leeuwen, P.J., Boormans, J.L, & Bangma, C.H. (2018). Abirateron in combinatie met androgeendeprivatietherapie bij patiënten met hormoonnaïef gemetastaseerd prostaatcarcinoom: Is het tijdperk van androgeendeprivatie-monotherapie voorbij?. Tijdschrift voor Urologie, 8(4), 60–65. doi:10.1007/s13629-017-0196-x